编者按：2021年6月9~17日，第26届欧洲血液学协会（EHA）年会将通过在线虚拟的方式隆重举行。这将是全球范围内的血液学医生、科学工作者面对COVID-19疫情，再次携手、集结力量的时刻！他们不畏挑战、不懈专研，努力探索治愈新生的可能性。
为给广大血液学科医生提供更新鲜、更精彩、更丰富的学术大餐，《肿瘤瞭望》特别设置了“EHA五分钟”专题报道。在EHA大会期间，“白血病、骨髓瘤、淋巴瘤”等各领域我们都将邀请以为专家精选出该领域的重磅研究，通过语音播报的形式，为您对大会内容进行介绍、解读与总结。
点评研究
Abstract #: S180
DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB， THALIDOMIDE， AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS
新诊断多发性骨髓瘤患者使用硼替佐米、沙利度胺和地塞米松（D-VTd）±自体干细胞移植(ASCT)治疗后使用达雷木单抗维持治疗vs观察：CASSIOPEIA试验第2部分结果
Abstract #: S181
DEPTH OF RESPONSE AND MRD STATUS IN ULTRA HIGH-RISK MYELOMA AND PLASMA CELL LEUKEMIA TREATED WITH DARA-CVRD AND AUGMENTED AUTOLOGOUS TRANSPLANT: RESULTS OF THE RISK-STRATIFIED UK OPTIMUM/MUKNINE TRIAL
DARA-CVRD和强化的自体移植治疗超高危骨髓瘤和浆细胞白血病的深层次的反应和MRD状态：基于危险分层的英国OPTIMUM/MUKNINE试验结果
Abstract #: S184
MEASURABLE RESIDUAL DISEASE (MRD) EVALUATION DURING IXAZOMIB (IXA) MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A LARGE ANALYSIS OF 1280 PATIENTS (PTS) ENROLLED IN TOURMALINE-MM3 AND -MM4
新诊断多发性骨髓瘤患者在伊沙佐米 (IXA)维持期间的MRD评估:对1280名纳入TOURMALINE-MM3 和 -MM4试验患者的大型分析
?
点评研究
Abstract #: S145
FIRST RESULTS OF A HEAD-TO-HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
阿卡拉布鲁替尼与伊布替尼治疗慢性淋巴细胞白血病的头对头试验的初步结果
Abstract #: S146
VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4-YEAR FOLLOW-UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY
VENETOCLAX-OBINUTUZUMAB初始治疗慢性淋巴细胞白血病：随机CLL14研究的4年随访分析
Abstract #: S149
MRD-GUIDED OR FIXED 12 CYCLES OF VENETOCLAX CONSOLIDATION AFTER VENETOCLAX PLUS OBINUTUZUMAB TREATMENT IN FIRST-LINE FCR UNFIT PATIENTS WITH CLL: PRIMARY ENDPOINT ANALYSIS OF THE HOVON 139/GIVE TRIAL
MRD引导或固定12个疗程的VENETOCLAX联合OBINUTUZUMAB治疗一线FCR不适合的CLL患者：HOVON 139/GIVE试验的主要终点分析
点评研究
Abstract #:S131
SURVIVAL OUTCOMES FROM THE QUAZAR AML-001 TRIAL WITH ORAL AZACITIDINE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA IN REMISSION BY DISEASE SUBTYPE， CYTOGENETIC RISK， AND NPM1 MUTATION STATUS AT DIAGNOSIS
QUAZAR AML-001临床试验生存结果：口服阿扎胞苷治疗已达到缓解的不同亚组AML患者（根据疾病亚型、细胞遗传学风险和诊断时NPM1突变状态）
Abstract #:S135
EFFICACY AND SAFETY OF VENETOCLAX IN COMBINATION WITH GILTERITINIB FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: UPDATED ANALYSES OF A PHASE 1B STUDY
维奈克拉联合吉瑞替尼治疗复发/难治FLT3突变急性髓系白血病的有效性和安全性评价:一项1b期研究的最新分析
Abstract #:S128
STANDARDIZING NGS-MRD IN AML: AN INTERNATIONAL STUDY BY THE ELN-MRD WORKING PARTY
规范AML患者NGS-MRD检测标准：一项由ELN-MRD 工作组开展的国际性研究
点评研究
Abstract #:S112
UPDATED RESULTS OF THE GIMEMA LAL2116， D-ALBA TRIAL， FOR NEWLY DIAGNOSED ADULTS WITH PH+ ALL
Dasatinib联合Blinatumomab 用于成人初治 Ph+ ALL 患者的一线治疗：GIMEMA LAL2116 D-ALBA试验的更新结果
Abstract #:S113
INTERIM RESULTS OF A PHASE II STUDY OF BLINATUMOMAB PLUS PONATINIB FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
一项关于Blinatumomab联合Ponatinib用于费城染色体阳性的急性淋巴细胞白血病的II期临床试验的中期结果
Abstract #:S114
PRELIMINARY RESULTS OF THE GIMEMA LAL2317 SEQUENTIAL CHEMOTHERAPY-BLINATUMOMAB FRONT-LINE TRIAL FOR NEWLY DIAGNOSED ADULT PH-NEGATIVE B-LINEAGE ALL PATIENTS
GIMEMA LAL2317：化疗序贯Blinatumomab用于成人初治PH阴性 B 淋巴细胞白血病一线治疗的初步结果?
点评研究
Abstract #:S205
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR PATIENTS WITH PREVIOUSLY UNTREATED， STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA: A 5-YEAR UPDATE OF THE PHASE 3 ECHELON-1 STUDY (NCT01712490)
本妥昔单抗联合化学疗法治疗先前未治疗的III期或IV期经典霍奇金淋巴瘤：第3阶段ECHELON-1研究的5年更新（NCT01712490）
Abstract #:S206
CAMRELIZUMAB FOR RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: THREE-YEAR OUTCOME OF A MULTICENTER， PHASE 2 STUDY
卡瑞利珠单抗于复发或难治性经典霍奇金淋巴瘤：三年多中心研究phase II研究
Abstract #:S208
PREDICTIVE VALUE OF QUANTITATIVE 18F-FDG-PET RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA
18F-FDG PET放射组学定量分析在174例复发/难治性霍奇金淋巴瘤中的预测价值
京公网安备 11010502033352号